F8 and autoimmune hemolytic anemia: The pharmacological concept of emicizumab, mimicking FVIII if its levels are low but being displaced from binding sites as soon as FVIII levels recover (due to the much higher affinity of FVIII), offers the following interesting possibilities also in AHA: prevention of spontaneous bleeding; subcutaneous application during long intervals; outpatient management of patients; and no more need for intensive immunosuppression [68,69].